Our lead program, TNG908, a protein arginine methyl transferase 5 (PRMT5) inhibitor that is synthetic lethal with MTAP deletion, is being developed as a treatment for cancers with MTAP deletions. Loss of MTAP is not tumor-promoting by itself, but is linked to the deletion of CDKN2A, a frequently deleted tumor suppressor gene. MTAP deletions occur in 10% to 15% of all human cancers, including many common cancers with high unmet need such as squamous cell lung, esophageal and bladder cancer, creating a significant therapeutic opportunity for patients.
A powerful approach
We are leveraging the principle of synthetic lethality and the power and productivity of our discovery engine to discover and validate multiple novel targets each year. Our growing pipeline consists of programs for genetically defined subsets of multiple cancers which have limited treatment options. Our pipeline is summarized below: